Incyte (INCY) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.47% |
| Dec 31, 2025 | 14.84% |
| Sep 30, 2025 | 97.30% |
| Jun 30, 2025 | 6.89% |
| Mar 31, 2025 | 17.29% |
| Dec 31, 2024 | 12.63% |
| Sep 30, 2024 | -3.66% |
| Jun 30, 2024 | -44.14% |
| Mar 31, 2024 | 10.63% |
| Dec 31, 2023 | 23.83% |
| Sep 30, 2023 | 42.47% |
| Jun 30, 2023 | 31.18% |
| Mar 31, 2023 | 20.38% |
| Dec 31, 2022 | 16.98% |
| Sep 30, 2022 | 25.62% |
| Jun 30, 2022 | 71.72% |
| Mar 31, 2022 | 17.11% |
| Dec 31, 2021 | 129.41% |
| Sep 30, 2021 | 37.57% |
| Jun 30, 2021 | 34.13% |
| Mar 31, 2021 | 17.36% |
| Dec 31, 2020 | 22.12% |
| Sep 30, 2020 | 17.42% |
| Jun 30, 2020 | 99.03% |
| Mar 31, 2020 | -108.34% |
| Dec 31, 2019 | 38.00% |
| Sep 30, 2019 | 16.69% |
| Jun 30, 2019 | 37.17% |
| Mar 31, 2019 | 38.04% |
| Dec 31, 2018 | 29.28% |
| Sep 30, 2018 | 27.15% |
| Jun 30, 2018 | 86.19% |
| Mar 31, 2018 | -21.30% |
| Dec 31, 2017 | -58.39% |
| Sep 30, 2017 | 29.63% |
| Jun 30, 2017 | -38.48% |
| Mar 31, 2017 | -32.72% |
| Dec 31, 2016 | 16.66% |
| Sep 30, 2016 | 21.93% |
| Jun 30, 2016 | 21.65% |
| Mar 31, 2016 | 23.79% |
| Dec 31, 2015 | 11.14% |
| Sep 30, 2015 | -4.54% |
| Jun 30, 2015 | 25.01% |
| Mar 31, 2015 | 12.47% |